ArticleJournal of gastroenterology and hepatology2026

Comparative Effectiveness and Safety of Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab as First-Line Systemic Therapy for Hepatocellular Carcinoma: A Real-World Study.

Shu Hsien Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.